Alemtuzumab, an anti-CD52 antibody targeting mature lymphocytes of both T and B cell origin, has been shown to deplete all circulating and recirculating T cells including central and effector memory T cells, but sparing TRMs, thus effectively treating leukemic CTCL but not MF [62,63]. Here, CD52 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.